Publication: British Journal of Clinical Pharmacology
Abstract
Rotigotine extended-release microspheres offer a weekly intramuscular injection option for Parkinson's disease, but potential ethnic differences in its pharmacokinetics had not been characterized. This study pooled data from clinical trials in China, Japan, and the US to build a population pharmacokinetic model with Phoenix NLME, examining covariates including body weight, sex, and race. Body weight was the primary driver of exposure differences, with lighter patients showing meaningfully higher exposure than heavier patients, while race showed only a modest effect on exposure that did not warrant dosage adjustment. The findings indicate that rotigotine extended-release dosing should account for body weight but does not need adjustment based on racial identity.
Author(s): Sun H, Dong C, Wu M, Li X, Song H, Zhang Y, Liu C, Liu P, Liu W, Chan P
Published: 2024 年 1 月 17 日
Phoenix NLME：Weight Matters More Than Ethnicity
Phoenix NLME pooled data across three countries in this rotigotine study, showing body weight, not race, should guide dose adjustments. Phoenix NLME can be paired with Model Designer to select, configure, and simulate models directly in the browser, guided by an AI assistant, within a Phoenix platform built on a validated, secure foundation.
